- A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
-
Soen S, Arai Y, Matsuda S, Emori K, Ikezaki T, Osawa M
- KMID: 2509979
- Osteoporos Sarcopenia.
- 2020 Dec;6(4):191-198.
- doi: 10.1016/j.afos.2020.11.002
Objectives This postmarketing study aims to evaluate the safety and effectiveness of oral administration of risedronate at 75 mg once monthly for 36 months in patients with osteoporosis in Japan. Methods Participants were... -
- CITED
-
- Close
- SHARE
-
- Close
